JD Health International Inc

JD Health maintains a highly conservative capital structure characterized by minimal leverage and substantial liquidity. The company reports a debt-to-equity ratio of 0.01, indicating negligible reliance on long-term debt financing. Total equity stands at 60.07 billion CNY, significantly outweighing total liabilities of 21.51 billion CNY. The balance sheet is fortified by 31.78 billion CNY in cash and equivalents, providing a robust buffer against operational shocks. The current ratio of 2.72 further confirms strong short-term solvency, allowing the firm to comfortably meet its immediate obligations. This liquidity profile supports a low liquidity risk assessment, with no immediate filing-based flags detected.

Profitability metrics reflect a stable but moderate return profile. The company generated 5.38 billion CNY in net income on 73.44 billion CNY in revenue, resulting in a net margin of approximately 7.3%. Return on equity (ROE) is recorded at 8.95%, while return on assets (ROA) stands at 6.59%. These returns are supported by an operating income of 4.71 billion CNY, demonstrating effective cost management within the retail healthcare segment. The gross profit of 18.20 billion CNY indicates a gross margin of roughly 24.8%, consistent with the economics of a broadline retailer that balances high-volume, low-margin pharmaceutical sales with higher-margin specialty health products.

Revenue concentration and geographic exposure are not detailed in the available segment or geography data, limiting specific analysis of product mix or regional dependency. However, the classification as a broadline and specialty retailer suggests a diversified product offering across pharmaceuticals, medical devices, and health services. The absence of specific segment data precludes a granular assessment of revenue drivers, but the overall scale of 73.44 billion CNY in revenue underscores the company's significant market presence in China's digital healthcare ecosystem.

Growth trajectory analysis is constrained by the absence of historical period data in the input. Without multi-year revenue or net income trends, it is not possible to quantify year-over-year growth rates or identify acceleration or deceleration patterns. The current financial snapshot provides a static view of performance, highlighting the company's current scale but not its historical momentum.

Risk factors are assessed as low for both liquidity and dilution. The company has no immediate filing-based liquidity or dilution flags, suggesting a stable share count and manageable cash flow requirements. The basic and diluted shares outstanding are identical at 3.21 billion, indicating no significant dilutive securities currently impacting earnings per share. This stability reduces uncertainty for equity holders regarding potential value erosion from share issuance.

Recent events and market sentiment reflect strong analyst confidence. The mean price target is 71.86 CNY, with a median of 67.44 CNY, significantly above the current market price of 37.30 CNY. The mean recommendation of 1.88 (on a scale where 1 is strong buy) indicates a bullish consensus, supported by 4 strong-buy and 11 buy ratings. This positive sentiment suggests that analysts view the company's current valuation as attractive relative to its growth potential and market position.

Revenue grew 26.3% year-over-year to CNY 73.4 billion in FY2026, demonstrating strong top-line expansion momentum.

Net income surged 29.2% to CNY 5.4 billion in FY2026, indicating robust profitability growth alongside revenue gains.

Free cash flow improved significantly to CNY 5.5 billion in FY2026, reflecting enhanced operational cash generation capabilities.

Long-term debt increased to CNY 258 million in FY2025, suggesting a gradual rise in leverage obligations over time.

Revenue ¥73.44B, +26,3% YoY; Operating income +45,1% YoY.

• ▍Revenue ¥73.44B, +26,3% YoY
• ▍Operating income +45,1% YoY
• ▍Net income +29,2% YoY
• ▍Free cash flow +27,1% YoY
• ▍Net margin 7.3%

Revenue ¥58.16B, +8,7% YoY; Operating income +262,9% YoY.

• ▍Revenue ¥58.16B, +8,7% YoY
• ▍Operating income +262,9% YoY
• ▍Net income +94,3% YoY
• ▍Free cash flow +88,0% YoY
• ▍Net margin 7.2%

Revenue ¥53.53B, +14,5% YoY; Operating income +2 412,2% YoY.

• ▍Revenue ¥53.53B, +14,5% YoY
• ▍Operating income +2 412,2% YoY
• ▍Net income +463,5% YoY
• ▍Free cash flow +231,6% YoY
• ▍Net margin 4.0%

Revenue ¥46.74B, +52,3% YoY; Operating income +102,9% YoY.

• ▍Revenue ¥46.74B, +52,3% YoY
• ▍Operating income +102,9% YoY
• ▍Net income +135,4% YoY
• ▍Free cash flow −14,5% YoY
• ▍Net margin 0.8%

Revenue ¥30.68B; Operating income -¥1.22B.

• ▍Revenue ¥30.68B
• ▍Operating income -¥1.22B
• ▍Net margin -3.5%